None listed
Conditions
Interventions
Drug : Patients were divided into two cohorts: one receiving Apixaban and the other not receiving Apixaban. They were observed for a period of six months from the time of diagnosis to compare the inci
Sponsors
Konkuk University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with locally advanced or metastatic pancreatic or biliary tract cancer (stage = 3), those with ECOG performance status = 2, and those who could be followed until death or for = 6 months from the time of diagnosis were included.
Exclusion criteria
Exclusion criteria: Patients aged 80 years old with severe mental disorders, a history of thrombosis unrelated to cancer, concurrent malignancies in other organs, current use of oral antiplatelet or other antithrombotic agents, a history of anticoagulant medication use for conditions such as atrial fibrillation, end-stage renal disease or creatinine clearance = 30 ml/min, ECOG performance status = 3, or a history of major bleeding events, including intracranial hemorrhage, gastrointestinal bleeding, or pulmonary hemorrhage, were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| occurence of thrombotic event | — |
Secondary
| Measure | Time frame |
|---|---|
| major hemorragic events;All-cause death | — |
Countries
Korea, Republic of
Contacts
Public ContactSemin Kim
Konkuk University Medical Center
Outcome results
None listed